--- title: "Expert Guide: Why Is MICM Integrated Diagnosis So Important in Hematologic Malignancies?" url: "https://www.yyhmedical.com/en/news/micm-integrated-diagnosis-hematologic-malignancy" type: Article inLanguage: en-US category: Expert Insights datePublished: 2026-03-06 --- # Expert Guide: Why Is MICM Integrated Diagnosis So Important in Hematologic Malignancies? > Dr. Chunrong TONG of Beijing GoBroad Boren Hospital explains how MICM integrated diagnosis combines four dimensions of testing to classify hematologic malignancies more precisely and support individualized treatment planning. Summary: Dr. Chunrong TONG of Beijing GoBroad Boren Hospital explains the central role of MICM integrated diagnosis in the care of malignant hematologic diseases. MICM brings together morphology, immunology, cytogenetics, and molecular biology, while an expanded MICM-PP framework also incorporates pathogen testing and pharmacology/pharmacogenomics. Together, these data can help clinicians define the disease more precisely, assess risk, and tailor treatment. Dr. Tong emphasizes that an accurate clinical diagnosis should never rely on a single laboratory report; medical history, family history, treatment and exposure history, and laboratory findings all need to be interpreted together. MICM integrated diagnosis combines Morphology (M), Immunology (I), Cytogenetics (C), and Molecular Biology (M), and is a core diagnostic framework for malignant hematologic diseases. In the expanded approach described here, pathogen-related testing (P) and pharmacology/pharmacogenomics (P) are also incorporated. Many patients and families still have questions about MICM integrated diagnosis. We therefore invited Dr. Chunrong TONG of Beijing GoBroad Boren Hospital to explain why integrated testing matters for precise disease classification and individualized treatment in hematologic malignancies. **What Is the Difference Between a Laboratory Result and a Clinical Diagnosis?** Patients often bring in a test report and ask, "Dr. Tong, the report says I have this disease. Does that mean this is definitely my diagnosis?" Not necessarily. A laboratory report gives one set of test results. What the medical team ultimately needs to establish is a complete clinical diagnosis. That diagnosis cannot be determined from a single report. It requires several types of information to be considered together, including laboratory findings as well as the patient's medical history, family history, medication history, and exposure history. For example, if a patient has had an elevated white blood cell count for 10 years, the clinical pattern may point more toward a chronic leukemia; if the change developed over only a few days, an acute leukemia may be more likely. This is why a detailed history matters. Another example is a patient who previously had a different cancer and received chemotherapy or radiotherapy, then later develops leukemia. In that setting, the leukemia may be secondary to prior treatment and classified as therapy-related leukemia. For such patients, the team may often consider allogeneic hematopoietic stem cell transplantation (allo-HSCT). A single piece of clinical history can therefore influence the overall treatment direction. Family history is also important. This is one reason clinicians may recommend testing for inherited susceptibility variants. Some diseases develop through an interaction between an underlying genetic predisposition and external triggers. Just as hypertension, diabetes, or certain cancers may cluster within families, a person's genetic background can also matter in hematologic disease. Medication and toxic-exposure history should also be reviewed. Long-term exposure to harmful substances may contribute to chromosomal instability and genetic mutations. According to the clinical framework described in this article, such patients may be less likely to achieve durable control with medication alone and may need transplantation to be considered. Allergy history and exposure to infectious diseases can also matter. One example is adult T-cell leukemia/lymphoma (ATLL), a virus-associated hematologic malignancy that is more common in certain endemic regions, including parts of coastal Japan and coastal Fujian in China. Without asking about relevant exposure and epidemiologic history, clinicians may be less likely to consider this diagnosis. Clinical information alone is still not enough. Laboratory and imaging data are also needed, including complete blood counts, bone marrow studies, and imaging. For hematologic malignancies, the article describes MICM-PP - adding Pathogen and Pharmacology (PP) components to MICM - as a comprehensive integrated diagnostic approach. **What Is MICM?** MICM is an integrated diagnostic and classification framework used in hematology. It combines four layers of testing to characterize disease from cell appearance and immune phenotype through chromosomes and genes. In practical terms, the four components are: \- M (Morphology): Evaluation of cell appearance under the microscope, together with cytochemical staining and histopathology. \- I (Immunology): Flow cytometry is used to analyze cell-surface markers, or antigens, while immunohistochemistry can assess marker expression in tissue. These methods help determine cell lineage and characteristics. Protein quantification or electrophoresis may also be used when needed. \- C (Cytogenetics): Testing looks for chromosomal abnormalities such as gains, losses, or translocations. Common methods include conventional karyotyping and fluorescence in situ hybridization (FISH). \- M (Molecular Biology): Molecular testing examines abnormalities at the gene level. This may include fusion-gene screening and quantification, mutation testing involving tumor-related genes, inherited susceptibility genes, and pharmacogenetic variants, copy-number analysis, IgH/TCR clonality testing to help determine whether a proliferation is neoplastic, pathogen-gene testing, and donor-recipient chimerism monitoring after transplantation. When these four layers of information are interpreted together, clinicians can classify the disease more precisely, estimate relapse risk, and identify potentially relevant targeted therapies, supporting a more individualized treatment strategy. **What Is MICM-PP?** MICM-PP expands the traditional MICM framework by adding two additional components beginning with the letter P, with the goal of supporting more precise individualized care: The first P - Pathogen testing: This looks for viral, bacterial, or other infectious agents, such as Epstein-Barr virus (EBV) or Helicobacter pylori. Methods may include pathogen-gene testing and pathogen assessment in tissue. The second P - Pharmacology and pharmacogenomics: Drug concentrations can be monitored together with genetic information related to drug metabolism, helping clinicians adjust dosing more precisely and safely. An accurate diagnosis is not determined by a single report. Morphology, immunology, cytogenetics, molecular biology, pathogen testing, pharmacology, and other information need to be integrated before a clear clinical conclusion can be reached and an appropriate treatment plan can be developed. Diagnosis is also not necessarily a one-time event. During treatment, the medical team may refine or update the diagnosis as the patient responds and new follow-up results become available. **What Is the Purpose of MICM Integrated Diagnosis?** Treatment for malignant hematologic diseases can be broadly divided into transplant and non-transplant approaches. Transplantation includes autologous and allogeneic hematopoietic stem cell transplantation. Non-transplant treatment may include surgery in selected situations, chemotherapy, targeted therapy, immunotherapy, hypomethylating therapy, and other approaches. With so many possibilities, MICM integrated diagnosis helps clinicians decide which pathway may be most appropriate for an individual patient. Whether a patient should undergo transplantation depends in part on disease-risk stratification. That risk assessment is built from multiple findings, including morphology, flow cytometry, cytogenetics, and molecular testing. The choice of transplant approach can also depend on the diagnostic findings. Autologous transplantation uses the patient's own stem cells, but the source article notes that inherited susceptibility variants or substantial prior treatment-related stem-cell injury may limit the suitability of this approach. In such situations, allogeneic transplantation may need to be considered. This is one reason inherited susceptibility testing can be relevant to later treatment planning. What Options Are Available If Transplantation Is Not Needed or Not Suitable? \- Surgery: Hematologic malignancies are usually systemic diseases and generally are not treated primarily with surgery. However, surgery may sometimes be considered when a large localized mass is compressing an important organ and symptom relief is needed. \- Chemotherapy: Not every hematologic malignancy is equally sensitive to chemotherapy. The source article gives chromosome 7 loss as one example associated with poorer chemotherapy response. \- Targeted therapy: Many targeted medicines are selected according to specific genetic alterations. Molecular testing can therefore help identify which therapies may be relevant. \- Immunotherapy: Treatments such as antibody-based therapies and CAR-T depend on the antigens expressed by tumor cells. For example, CD19-directed CAR-T therapy or blinatumomab requires an appropriate CD19-positive disease context. The purpose of performing multiple MICM tests is to answer practical treatment questions as clearly as possible: Does this patient need a transplant? If so, when? Which medicines should be used, in what combination and at what dose? What should the treatment goal be? Integrated diagnostic data help inform each of these decisions. **Case Example** *A 47-year-old patient had skin bleeding spots, fever, and fatigue for 17 days. At presentation, the white blood cell count was reported as 61. A peripheral blood smear from the local hospital occasionally showed immature monocytes, and blasts plus immature monocytes accounted for 65% of cells in the bone marrow.* *Based on morphology, the case could be diagnosed as acute monocytic leukemia. Flow cytometry was also consistent with acute myeloid leukemia (AML). However, the most important additional information came from molecular testing, which identified several mutations, including DNMT3A, NPM1, IDH1, and JAK2.* These molecular findings led to several important clinical interpretations: **First: Reassessing Risk Stratification** If cytogenetics alone were considered, the patient's karyotype was normal and would traditionally have placed the patient in an intermediate-risk group. The molecular findings changed that interpretation: multiple mutations were considered adverse prognostic features. More importantly, after chemotherapy-induced remission, the DNMT3A mutation remained detectable at a variant frequency of 29%. The treating team interpreted this persistence as evidence of an underlying abnormal hematopoietic clone, with implications for relapse risk and the possibility of additional hematologic malignancy after repeated chemotherapy. Despite the normal karyotype, the patient was therefore ultimately classified as high risk. This illustrates the independent prognostic value of molecular information: it can reveal risk that conventional cytogenetics may not capture. **Second: Helping Guide Drug Selection** The source article notes that several mutations may provide potential treatment targets. It states that DNMT3A mutation may suggest sensitivity to hypomethylating agents such as decitabine or azacitidine; NPM1-mutated disease may be treated in combination with all-trans retinoic acid (ATRA); JAK2 mutation may prompt consideration of a JAK inhibitor such as ruxolitinib; and IDH2-mutated disease has available IDH2 inhibitors. Based on this framework, an initial regimen containing a hypomethylating agent - for example, decitabine combined with venetoclax - may be considered, with additional targeted agents added according to the clinical situation. **Third: Determining Whether Transplantation Is Needed** The article states that cure rates with chemotherapy alone are below 40% for intermediate-risk AML. In this case, the patient also had several high-risk features, including a high white blood cell count at diagnosis, DNMT3A, GATA2, and JAK2 mutations described as adverse prognostic findings, and persistence of the DNMT3A clone after remission. The treating team therefore concluded that chemotherapy alone would be insufficient. The recommendation was to first achieve complete remission and then proceed to allogeneic hematopoietic stem cell transplantation (allo-HSCT) as soon as appropriate. After transplantation, the source article notes that agents such as ATRA or JAK inhibitors may also be considered as targeted strategies to help reduce relapse risk. **Fourth: Planning Long-Term Monitoring** The patient had an NPM1 mutation, which can be used as a molecular marker for follow-up. Quantitative PCR can be performed at regular intervals, and flow cytometry can be used to monitor measurable residual disease (MRD). When needed, deep sequencing of additional genes can provide further quantitative information. Using several complementary methods can give the clinical team a more complete picture of treatment response. **What Does This Case Show?** **Morphology indicated acute monocytic leukemia.** **Flow cytometry showed a myeloid malignancy with monocytic differentiation.** **Cytogenetics showed a normal karyotype, which would traditionally suggest intermediate risk.** **Molecular testing, however, indicated a higher-risk patient, identified potential treatment targets, provided measurable markers for follow-up, and supported the need to consider transplantation.** This is the value of integrated diagnosis: each layer of information contributes to a treatment decision - which medicines to use, how deep a response to aim for, whether transplantation is needed, and how response should be monitored. Treatment decisions should be built on these clinical and laboratory data rather than on a single test in isolation. The goal of integrated diagnosis is not to make testing more complicated, but to make treatment more precise. When the direction is clearer from the start, each subsequent step can be planned with greater confidence. --- Original (HTML):https://www.yyhmedical.com/en/news/micm-integrated-diagnosis-hematologic-malignancy This is a clean Markdown mirror for large language models; the original page is authoritative.